Omicron News and Research

RSS

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

Researchers compared the efficacy of sotrovimab and molnupiravir in preventing severe COVID-19 outcomes among non-hospitalized and high-risk COVID-19 patients across England.

25 May 2022

Largest study to date on long COVID identifies a broad list of diagnoses

Researchers characterize post-acute sequelae of SARS-CoV-2 infection.

25 May 2022

Study compares excess mortality in Massachusetts during the Delta and initial Omicron periods

Researchers estimated excess mortality in Massachusetts during the COVID-19 Delta and early Omicron waves.

24 May 2022

Hamster contact exposure challenge model assesses protection conferred by SARS-CoV-2 vaccination or prior infection against reinfection

Researchers assessed the neutralization efficacy of a saRNA vaccine targeting SARS-CoV-2 S protein against reinfection among hamsters with prior vaccination or infection.

24 May 2022

The effects of maternal SARS-CoV-2 infection on the newborn child

Even as the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide, interest in understanding the sequelae of the disease is growing. A new preprint research paper examines the outcomes of babies born to mothers infected with the virus during pregnancy.

24 May 2022

Efficacy study of Paxlovid and Molnupiravir in real-world settings shows positive results

In a recent study posted to the medRxiv* pre-print server, researchers evaluated the effectiveness of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, molnupiravir (Lagevrio) or nirmatrelvir/ritonavir (Paxlovid) in a real-world setting.

24 May 2022

Omicron vaccine breakthrough infections induce potent cross-reactive antibodies

In a recent study published in the journal Cell, researchers demonstrated that antibodies generated due to breakthrough infection (BTI) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) new variant of concern (VOC) Omicron in vaccinated individuals could neutralize all VOCs.

24 May 2022

BNT162b2 vaccine induces robust SARS-CoV-2 immunity in children

In a recent study posted to the medRxiv* pre-print server, researchers evaluated coronavirus disease 2019 (COVID-19) vaccine-induced humoral immune response in five to 11-year-old children.

23 May 2022

Study reveals the cross-protective role of Omicron infection in vaccinated individuals

A new study compares the cross-protective humoral responses to different SARS-CoV-2 variants induced by vaccination or infection.

23 May 2022

ATLAS assay reveals SARS-CoV-2 variant T-cell responses

Researchers utilize the ATLAS screening assay to reveal the antigen response profiles of T-cells to different SARS-CoV-2 variants.

23 May 2022

Health authorities must revolutionize testing to deal with future covid-19 prevalence

Dealing with lower covid-19 levels will require improved understanding of what diagnostic tests are best used for. It will also need more accurate tests, but as testing demand will fall, delivering that needs incentive-based support.

23 May 2022

Study shows the QuickNavi-COVID19 Ag test has a high diagnostic performance for SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in nasopharyngeal samples

Researchers evaluated the diagnostic performance of a COVID-19 antigen test during the recent surge caused by the SARS-CoV-2 Omicron variant.

23 May 2022

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Resarchers discuss the ability of shark-derived antibodies to protect against multiple variants of SARS-CoV-2.

23 May 2022

Women who are pregnant or nursing should receive a COVID booster vaccination

In a recent study posted to the medRxiv* preprint server, researchers evaluated the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster vaccination in nursing and pregnant women.

23 May 2022

SARS-CoV-2 Omicron subvariants are increasingly escaping immunity

In a recent study posted to the medRxiv* preprint server, researchers evaluated the neutralization evasion of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages.

22 May 2022

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Researchers determine whether mutations in the Omicron NTD influence its potential to stimulate myeloid cells and enhance inflammatory cytokine release.

22 May 2022

Higher excess mortality found in Massachusetts during Omicron period than the Delta period

The COVID-19 pandemic has led to excess deaths - a higher number of fatalities than would be expected over a given period.

22 May 2022

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

A new study has revealed that ATV006, which is a 5′-hydroxyl-isobutyryl prodrug, possesses extraordinary oral pharmaco-kinetic (PK) profiles in rats and cynomolgus monkeys and exhibited significant antiviral activity against ancestral SARS-COV-2 strain as well as VOCs.

20 May 2022

High-tech’s business model hasn’t worked for the cue covid test

"I've got this," coos Gal Gadot in Cue Health's Super Bowl TV commercial. Cue hired the "Wonder Woman" actress to be the voice of the company's new high-tech covid-19 testing device.

20 May 2022

Exploring cross-neutralizing anti-SARS-CoV-2 antibody responses among the general population

Researchers performed a molecular analysis of cross-reactive antibodies targeted against the receptor-binding domain of SARS-CoV-2 strains among the general population.

20 May 2022

Omicron News and Research

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

Largest study to date on long COVID identifies a broad list of diagnoses

Study compares excess mortality in Massachusetts during the Delta and initial Omicron periods

Hamster contact exposure challenge model assesses protection conferred by SARS-CoV-2 vaccination or prior infection against reinfection

The effects of maternal SARS-CoV-2 infection on the newborn child

Efficacy study of Paxlovid and Molnupiravir in real-world settings shows positive results

Omicron vaccine breakthrough infections induce potent cross-reactive antibodies

BNT162b2 vaccine induces robust SARS-CoV-2 immunity in children

Study reveals the cross-protective role of Omicron infection in vaccinated individuals

ATLAS assay reveals SARS-CoV-2 variant T-cell responses

Health authorities must revolutionize testing to deal with future covid-19 prevalence

Study shows the QuickNavi-COVID19 Ag test has a high diagnostic performance for SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in nasopharyngeal samples

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Women who are pregnant or nursing should receive a COVID booster vaccination

SARS-CoV-2 Omicron subvariants are increasingly escaping immunity

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Higher excess mortality found in Massachusetts during Omicron period than the Delta period

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

High-tech’s business model hasn’t worked for the cue covid test

Exploring cross-neutralizing anti-SARS-CoV-2 antibody responses among the general population

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News